Cargando…

A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib

Echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) rearrangements are found in ~ 5% of patients with non‐small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so‐called ALK‐positive NSCLC. In cases of tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsumura, Yuki, Inomata, Sho, Yamaguchi, Hikaru, Mine, Hayato, Takagi, Hironori, Watanabe, Masayuki, Ozaki, Yuki, Yamaura, Takumi, Fukuhara, Mitsuro, Muto, Satoshi, Okabe, Naoyuki, Hasegawa, Takeo, Shio, Yutaka, Suzuki, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327688/ https://www.ncbi.nlm.nih.gov/pubmed/34159737 http://dx.doi.org/10.1111/1759-7714.14058

Ejemplares similares

Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: A case report
por: Watanabe, Masayuki, et al.
Publicado: (2022)

Thoracoscopic resection of posterior mediastinal paraganglioma: perioperative management and surgical tips
por: Matsumura, Yuki, et al.
Publicado: (2022)

Ectopic adrenocorticotropic hormone‐secreting carcinoid with solitary cryptococcosis in the lungs
por: Takagi, Hironori, et al.
Publicado: (2022)

Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers
por: Muto, Satoshi, et al.
Publicado: (2023)

Our experience of lung resection in patients who decline blood transfusion for religious reasons
por: Takagi, Hironori, et al.
Publicado: (2021)

Tumor β-catenin expression is associated with immune evasion in non-small cell lung cancer with high tumor mutation burden
por: Muto, Satoshi, et al.
Publicado: (2021)

Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature
por: Hasegawa, Takeo, et al.
Publicado: (2019)

Pulmonary large cell carcinoma, highly positive for PD‐L1, shows marked response to pembrolizumab: A case report
por: Okabe, Naoyuki, et al.
Publicado: (2021)

Lung adenocarcinoma coexisting with diffuse idiopathic pulmonary neuroendocrine cell hyperplasia manifesting as multiple pulmonary nodules: A case report
por: Inomata, Sho, et al.
Publicado: (2022)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

ALK Rearrangement Adenocarcinoma with Histological Transformation to Squamous Cell Carcinoma Resistant to Alectinib and Ceritinib
por: Kaiho, Taisuke, et al.
Publicado: (2020)

Family with sequence similarity 83, member B is a predictor of poor prognosis and a potential therapeutic target for lung adenocarcinoma expressing wild-type epidermal growth factor receptor
por: Yamaura, Takumi, et al.
Publicado: (2018)

The efficacy of the Kampo medicine rikkunshito for chemotherapy-induced anorexia (RICH trial): study protocol for a randomized controlled trial
por: Inoue, Takuya, et al.
Publicado: (2017)

CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
por: Watanabe, Masayuki, et al.
Publicado: (2021)

Prognostic Impact of Hypoxia-Inducible miRNA-210 in Patients with Lung Adenocarcinoma
por: Osugi, Jun, et al.
Publicado: (2015)

Clinical significance of expanded Foxp3(+) Helios(−) regulatory T cells in patients with non-small cell lung cancer
por: MUTO, SATOSHI, et al.
Publicado: (2015)

Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with EGFR-TKIs plus Bevacizumab: A Case Report
por: Muto, Satoshi, et al.
Publicado: (2020)

Diffuse Cystic Metastases in the Lung after Nivolumab Treatment in a Patient with Non-Small Cell Lung Cancer: A Case Report
por: Muto, Satoshi, et al.
Publicado: (2021)

ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells
por: Dong, Xuyuan, et al.
Publicado: (2016)

A case of ALK-rearranged non–small cell lung cancer that responded to ceritinib after development of resistance to alectinib
por: Makuuchi, Yosuke, et al.
Publicado: (2018)

Efficacy of Crizotinib, Ceritinib, and Alectinib in ALK-Positive Non-Small Cell Lung Cancer Treatment: A Meta-Analysis of Clinical Trials
por: Hoang, Tung, et al.
Publicado: (2020)

Assessment of Alectinib vs Ceritinib in ALK-Positive Non–Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data
por: Wilkinson, Samantha, et al.
Publicado: (2021)

Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report
por: Osugi, Jun, et al.
Publicado: (2016)

A case of discordant histology and expression of programmed death ligand 1 between primary tumor and brain metastases in adenosquamous carcinoma of the lung
por: Takagi, Hironori, et al.
Publicado: (2023)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer
por: Higuchi, Mitsunori, et al.
Publicado: (2016)

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status
por: Kitadai, Rui, et al.
Publicado: (2018)

Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
por: Suzuki, Hiroyuki, et al.
Publicado: (2013)

Clinical Impact of Switching to Ceritinib After Severe AEs Related to Crizotinib/Alectinib in a Novel PTH2R-ALK Fusion Lung Adenocarcinoma: A Case Report
por: Shen, Gang, et al.
Publicado: (2021)

Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
por: van Erp, Anke E. M., et al.
Publicado: (2017)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
por: Santarpia, Mariacarmela, et al.
Publicado: (2017)

Garcin syndrome caused by sphenoid bone metastasis of lung cancer: a case study
por: Fukai, Satoshi, et al.
Publicado: (2018)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Dramatic response to alectinib in a patient with ALK‐rearranged squamous cell lung cancer
por: Shiihara, Jun, et al.
Publicado: (2021)

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
por: Burns, Mark W, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7sg8u5ji297qcfn0qc0u81frkt